3.86
price down icon0.64%   -0.02
after-market アフターアワーズ: 3.85 -0.010 -0.26%
loading
前日終値:
$3.88
開ける:
$3.92
24時間の取引高:
2.99M
Relative Volume:
0.64
時価総額:
$1.01B
収益:
$194.75M
当期純損益:
$-51.26M
株価収益率:
-13.79
EPS:
-0.28
ネットキャッシュフロー:
$-23.38M
1週間 パフォーマンス:
-1.91%
1か月 パフォーマンス:
+8.29%
6か月 パフォーマンス:
+86.23%
1年 パフォーマンス:
+183.46%
1日の値動き範囲:
Value
$3.83
$3.97
1週間の範囲:
Value
$3.81
$4.00
52週間の値動き範囲:
Value
$1.07
$4.0787

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name
名前
Akebia Therapeutics Inc
Name
セクター
Healthcare (1171)
Name
電話
617-871-2098
Name
住所
245 FIRST STREET, CAMBRIDGE, MA
Name
職員
181
Name
Twitter
@akebiatx
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
AKBA's Discussions on Twitter

AKBA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
AKBA
Akebia Therapeutics Inc
3.86 1.05B 194.75M -51.26M -23.38M -0.28
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
148.60 70.70B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.43 46.87B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.60 45.41B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.06 18.96B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
292.01 13.54B 2.99B 1.21B 1.13B 25.06

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-06-04 再開されました H.C. Wainwright Buy
2025-04-28 開始されました Leerink Partners Outperform
2025-04-01 開始されました Jefferies Buy
2023-11-29 再開されました BTIG Research Buy
2023-08-28 アップグレード H.C. Wainwright Neutral → Buy
2023-05-31 アップグレード Piper Sandler Neutral → Overweight
2022-03-31 ダウングレード H.C. Wainwright Buy → Neutral
2022-03-31 ダウングレード Mizuho Buy → Neutral
2022-03-31 ダウングレード Needham Buy → Hold
2022-03-31 ダウングレード Piper Sandler Overweight → Neutral
2021-03-08 開始されました Cantor Fitzgerald Overweight
2021-01-29 ダウングレード JP Morgan Neutral → Underweight
2019-11-14 繰り返されました Needham Buy
2019-08-06 繰り返されました H.C. Wainwright Buy
2019-07-11 繰り返されました H.C. Wainwright Buy
2019-05-02 開始されました JP Morgan Overweight
2019-03-20 開始されました Citigroup Neutral
2018-09-07 再開されました Morgan Stanley Equal-Weight
2018-08-10 繰り返されました Needham Buy
2018-06-06 繰り返されました H.C. Wainwright Buy
2017-12-19 開始されました Piper Jaffray Overweight
2017-12-07 開始されました BTIG Research Buy
2017-09-15 開始されました RBC Capital Mkts Sector Perform
2017-07-10 繰り返されました H.C. Wainwright Buy
2017-04-27 繰り返されました H.C. Wainwright Buy
2017-04-27 繰り返されました Needham Buy
2016-12-27 繰り返されました H.C. Wainwright Buy
2016-12-20 繰り返されました JMP Securities Mkt Outperform
2016-11-15 開始されました Aegis Capital Buy
2016-09-29 開始されました Brean Capital Buy
2016-03-16 繰り返されました Needham Buy
2016-01-21 開始されました Credit Suisse Neutral
すべてを表示

Akebia Therapeutics Inc (AKBA) 最新ニュース

pulisher
09:23 AM

What analysts say about Akebia Therapeutics Inc. stockStrongest growth potential - Jammu Links News

09:23 AM
pulisher
01:24 AM

Akebia Therapeutics, Inc. (AKBA) Shareholders Greenlight 18.9 Million Share Increase - MSN

01:24 AM
pulisher
Jul 16, 2025

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of GATO, AKBA and LCID - ACCESS Newswire

Jul 16, 2025
pulisher
Jul 16, 2025

Akebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

PHD inhibitors reported in Akebia Therapeutics patent - BioWorld MedTech

Jul 16, 2025
pulisher
Jul 14, 2025

Transcript : Akebia Therapeutics, Inc. Presents at H.C. Wainwright 4th Annual Kidney Virtual Conference, Jul-14-2025 10 - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Akebia at H.C. Wainwright: Strategic Insights on Kidney Care Products By Investing.com - Investing.com Canada

Jul 14, 2025
pulisher
Jul 12, 2025

Akebia Ther stock hits 52-week high at 4.08 USD - Investing.com Australia

Jul 12, 2025
pulisher
Jul 11, 2025

Akebia Ther stock hits 52-week high at 4.08 USD By Investing.com - Investing.com Nigeria

Jul 11, 2025
pulisher
Jul 08, 2025

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

Upcoming Kidney Disease Conference: Akebia CCO to Share Latest Commercial Strategy - Stock Titan

Jul 08, 2025
pulisher
Jul 07, 2025

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees - MSN

Jul 07, 2025
pulisher
Jul 07, 2025

Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT - Insider Monkey

Jul 07, 2025
pulisher
Jul 07, 2025

13 Stocks Under $5 With High Upside Potential - Insider Monkey

Jul 07, 2025
pulisher
Jul 03, 2025

Akebia Therapeutics Reports Positive Results from its Vadadustat Global Phase 3 Clinical Trials - MSN

Jul 03, 2025
pulisher
Jul 01, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 01, 2025
pulisher
Jul 01, 2025

Just Announced: Akebia Therapeutics Expands Team with 141,800 Share Options at $3.64 Strike Price - Stock Titan

Jul 01, 2025
pulisher
Jun 26, 2025

15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey

Jun 26, 2025
pulisher
Jun 23, 2025

Exploring 3 High Growth Tech Stocks In The US Market - Yahoo Finance

Jun 23, 2025
pulisher
Jun 18, 2025

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 34% Share Price Rise - simplywall.st

Jun 18, 2025
pulisher
Jun 17, 2025

AVEROA - The Pharma Letter

Jun 17, 2025
pulisher
Jun 16, 2025

AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - The Manila Times

Jun 16, 2025
pulisher
Jun 16, 2025

AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - GlobeNewswire Inc.

Jun 16, 2025
pulisher
Jun 13, 2025

Akebia Therapeutics expands stock incentive plan - Investing.com Australia

Jun 13, 2025
pulisher
Jun 13, 2025

Akebia Therapeutics expands stock incentive plan By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Akebia Therapeutics Approves Stock Plan Amendment at Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 07, 2025

Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026 - Seeking Alpha

Jun 07, 2025
pulisher
Jun 07, 2025

Day 7 of Gains Streak for Akebia Therapeutics Stock with 38% Return (vs. 109% YTD) [6/6/2025] - Trefis

Jun 07, 2025
pulisher
Jun 06, 2025

H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

Akebia Therapeutics at Jefferies Conference: Strategic Growth Insights By Investing.com - Investing.com Canada

Jun 06, 2025
pulisher
Jun 05, 2025

Organizational Transitions, Patient Enrollment, Initiation of Clinical Programs, Financial Outlook, and Corporate UpdatesA... - ADVFN

Jun 05, 2025
pulisher
Jun 04, 2025

Akebia reports mixed results for anemia drug in global study By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before Buying - Seeking Alpha

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia reports mixed results for anemia drug in global study - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia Therapeutics (AKBA) Receives 'Buy' Rating from HC Wainwri - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia (AKBA) Publishes Phase 3 Clinical Trial Analysis | AKBA S - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia Therapeutics Announces Publication of Pre-specified Analyses on Vadadustat from Global Phase 3 Clinical Program in Journal of the American Society of Nephrology - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

Vadadustat U.S. Patient Data from Global Phase 3 Clinical - GlobeNewswire

Jun 04, 2025
pulisher
Jun 04, 2025

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

H.C. Wainwright assumes coverage on Akebia Therapeutics stock with buy rating - Investing.com

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia (AKBA) Receives Buy Rating with Promising Outlook for Vaf - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia Ther stock soars to 52-week high, hits $3.31 By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 03, 2025

Akebia Ther stock soars to 52-week high, hits $3.31 - Investing.com Australia

Jun 03, 2025

Akebia Therapeutics Inc (AKBA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$73.36
price up icon 0.10%
$15.04
price up icon 0.53%
$9.155
price down icon 1.08%
drug_manufacturers_specialty_generic RDY
$14.65
price down icon 0.27%
$133.71
price up icon 0.13%
$297.38
price up icon 0.39%
大文字化:     |  ボリューム (24 時間):